Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

A new aldosterone synthase inhibitor shows staying power. Lorundrostat sustained significant blood pressure reductions for up to 48 weeks in adults with uncontrolled or resistant hypertension, with a strong safety profile. A separate subgroup analysis also found the drug reduced both BP and urinary protein levels in patients with chronic kidney disease, pointing to broader cardiorenal benefits.
Lorundrostat, an aldosterone synthase inhibitor developed by Mineralys Therapeutics, is proving it has long-term staying power. Data from the Transform-HTN open-label extension trial — the largest long-term study of its kind — showed the drug delivered sustained blood pressure control over 48 weeks in adults with uncontrolled or resistant hypertension, even in patients already on two to five antihypertensive medications. Importantly, no clinically relevant safety concerns emerged over that period.
A separate subgroup analysis from the Launch-HTN trial adds another dimension to the story: lorundrostat also benefits patients with chronic kidney disease (CKD). The drug reduced systolic BP comparably in CKD and non-CKD patients, and cut urinary albumin levels — a key marker of kidney and cardiovascular health — by over 50% in those with albuminuria at baseline.
By the Numbers:
Why it matters: With resistant hypertension affecting millions and CKD compounding cardiovascular risk, lorundrostat's dual impact on blood pressure and kidney health could be clinically significant — potentially reducing pill burden and offering long-term protection for both heart and kidneys.